Live Breaking News & Updates on Swedish Psoriasis Association

Stay updated with breaking news from Swedish psoriasis association. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lipidor – update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis


Sök
Lipidor – update on the company’s phase III clinical trial of drug candidate AKP02 for treatment of psoriasis
Stockholm, Sweden, 22 April 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company s drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for commencement of the Phase III study. As Lipidor has previously announced, the main purpose of the study is to compare the therapeutic efficacy of AKP02 with existing medicines for mild to moderate psoriasis. Results from the study are expected in the first half of 2022. ....

Ola Holmlund , Swedish Psoriasis Association , Erik Penser Bank , Cadila Pharmaceuticals , ஏறிக் பென்சர் வங்கி , காடிலா மருந்துகள் ,

Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis


(0)
STOCKHOLM, April 22, 2021 /PRNewswire/ Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company s drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for commencement of the Phase III study. As Lipidor has previously announced, the main purpose of the study is to compare the therapeutic efficacy of AKP02 with existing medicines for mild to moderate psoriasis. Results from the study are expected in the first half of 2022.
AKP02 is a drug candidate for psoriasis that combines calcipotriol and betamethasone and is based on Lipidor s patented AKVANO technology. The aim with AKP02 is to offer a patient-friendly, spray-based treatment for mild to moderate plaque psoriasis. ....

Ola Holmlund , Swedish Psoriasis Association , Erik Penser Bank , Cadila Pharmaceuticals , Indian Medical Products Agency , Nasdaq First North , ஏறிக் பென்சர் வங்கி , காடிலா மருந்துகள் , நாஸ்டாக் முதல் வடக்கு ,

Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis

Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Ola Holmlund , Swedish Psoriasis Association , Erik Penser Bank , Cadila Pharmaceuticals , Indian Medical Products Agency , Nasdaq First North , ஏறிக் பென்சர் வங்கி , காடிலா மருந்துகள் , நாஸ்டாக் முதல் வடக்கு ,